

# Hepatitis C Tracking Data

(FY2021 Appropriation Act - Public Act 166 of 2020)

**March 1, 2021**

***Sec. 1878. By March 1 of the current fiscal year, the department shall provide a report to the senate and house appropriations subcommittees on the department budget, the senate and house fiscal agencies, the senate and house policy offices, and the state budget office on hepatitis C tracking data. At a minimum, the report shall include information on the following for individuals treated with Harvoni or any other treatment used to cure hepatitis C during the current fiscal year or a previous fiscal year:***

***(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.***

***(b) The total cost of treatment.***

***(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.***

***(d) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.***

***(e) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.***



# Hepatitis C Tracking Data

## Section 1878 PA 166 of 2020

**(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.**

In Fiscal Year 2019-2020, a total of 842 people were treated through traditional Medicaid and 1,314 people were treated through the Healthy Michigan Plan. There were 2,131 unique individuals treated, some individuals' eligibility fluctuated between programs during this time period.

**(b) The total cost of treatment.**

In Fiscal Year 2019-2020, a total of \$91,679,846 was spent on drugs designed to cure Chronic Hepatitis C.

**(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.**

In Fiscal Year 2019-2020, \$36,538,514 was spent on those treated through traditional Medicaid, while \$55,141,332 was spent on those treated through the Healthy Michigan Plan.

**(d) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment and (e) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.<sup>1</sup>**

To calculate the cure and reinfection rates for those receiving these treatments, practitioners who treated 2,131 patients with paid claims for these drugs from October 1, 2019 through September 30, 2020 were surveyed. If the department receives at least a 30% survey response rate, a revised report will be submitted.

---

<sup>1</sup>At this time, an insufficient number of surveys detailing the cure and reinfection rates broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment for Fiscal Year 2019-2020 have not been returned to the Department.